Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

EP: 1.Navigating mCRC: Treatment Options in the Third-Line Setting

EP: 2.Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP: 3.Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP: 4.Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

Now Viewing

EP: 5.Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP: 6.Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP: 7.Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP: 8.Unmet Needs in Third-Line mCRC: Challenges and Opportunities

1. How do the reported HRQOL data influence your treatment decisions? And how do you assess your patient’s symptoms or quality of life in a real-life practice setting?
2. How does the toxicity profile of each agent influence your treatment selection?

Related Videos